Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor

Hypoxia-inducible factor prolyl hydroxylase (PHD) inhibitors have been approved for treating renal anemia yet have failed clinical testing for inflammatory bowel disease because of a lack of efficacy. Here we used a multimodel multimodal generative artificial intelligence platform to design an orally gut-restricted selective PHD1 and PHD2 inhibitor that exhibits favorable safety and pharmacokinetic profiles in preclinical studies. ISM012-042 restores intestinal barrier function and alleviates gut inflammation in multiple experimental colitis models.

Authors

Institutions

Publication Details

Journal
Nature Biotechnology
Published
2024-12-11
DOI
https://doi.org/10.1038/s41587-024-02503-w
Citations
36
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
8.42
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor

Yushu Yin, Taotao Li, Frank W. Pun, Chenxi Xu et al.
36 citations
Nature Biotechnology
Gut microbiota and health
8.42
article

Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor

Yushu Yin, Taotao Li, Frank W. Pun, Chenxi Xu, Yaya Fan, David Gennert, Alex Zhavoronkov, Chunlei Feng, Petrina Kamya, Alexander Aliper, Liang Xing, Fadi E. Pulous, Man Zhang, Shan Chen, Ling Wang, Rui Wang, Ziqi Yan, Xiaoyu Ding, Yanyun Fu, Feng Ren, Jianyu Xu, Xiaoxia Lin, Xiao Ding
article en
36 citations

Abstract

Hypoxia-inducible factor prolyl hydroxylase (PHD) inhibitors have been approved for treating renal anemia yet have failed clinical testing for inflammatory bowel disease because of a lack of efficacy. Here we used a multimodel multimodal generative artificial intelligence platform to design an orally gut-restricted selective PHD1 and PHD2 inhibitor that exhibits favorable safety and pharmacokinetic profiles in preclinical studies. ISM012-042 restores intestinal barrier function and alleviates gut inflammation in multiple experimental colitis models.

Nature BiotechnologyVol. 43(11)
Insilicos (United States) (US), Insilico Medicine (United States)
Openalex Percentile: Top 1%
Gut microbiota and health
8.42
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.